Cancer Research Laboratory, University Hospital Research Center (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
J Mol Neurosci. 2014 Sep;54(1):27-40. doi: 10.1007/s12031-014-0241-7. Epub 2014 Jan 25.
Epigenetic alterations have been increasingly implicated in glioblastoma (GBM) pathogenesis, and epigenetic modulators including histone deacetylase inhibitors (HDACis) have been investigated as candidate therapies. GBMs are proposed to contain a subpopulation of glioblastoma stem cells (GSCs) that sustain tumor progression and therapeutic resistance and can form tumorspheres in culture. Here, we investigate the effects of the HDACi trichostatin A (TSA) in U87 GBM cultures and tumorsphere-derived cells. Using approaches that include a novel method to measure tumorsphere sizes and the area covered by spheres in GBM cultures, as well as a nuclear morphometric analysis, we show that TSA reduced proliferation and colony sizes, led to G2/M arrest, induced alterations in nuclear morphology consistent with cell senescence, and increased the protein content of GFAP, but did not affect migration, in cultured human U87 GBM cells. In cells expanded in tumorsphere assays, TSA reduced sphere formation and induced neuron-like morphological changes. The expression of stemness markers in these cells was detected by reverse transcriptase polymerase chain reaction. These findings indicate that HDACis can inhibit proliferation, survival, and tumorsphere formation, and promote differentiation of U87 GBM cells, providing further evidence for the development of HDACis as potential therapeutics against GBM.
表观遗传改变在胶质母细胞瘤(GBM)发病机制中越来越受到关注,包括组蛋白去乙酰化酶抑制剂(HDACi)在内的表观遗传调节剂已被研究作为候选治疗方法。GBM 被认为包含一小部分胶质母细胞瘤干细胞(GSCs),这些细胞维持肿瘤的进展和治疗抵抗,并能在培养中形成肿瘤球。在这里,我们研究了 HDACi 曲古抑菌素 A(TSA)在 U87 GBM 培养物和肿瘤球衍生细胞中的作用。我们使用了包括一种新的方法来测量肿瘤球的大小和 GBM 培养物中球体覆盖的面积,以及核形态计量分析在内的方法,表明 TSA 降低了增殖和集落大小,导致 G2/M 期阻滞,诱导与细胞衰老一致的核形态改变,并增加了 GFAP 的蛋白含量,但不影响迁移,在培养的人 U87 GBM 细胞中。在肿瘤球测定中扩增的细胞中,TSA 减少了球体的形成并诱导出类神经元的形态变化。通过逆转录聚合酶链反应检测这些细胞中干性标志物的表达。这些发现表明,HDACi 可以抑制 U87 GBM 细胞的增殖、存活和肿瘤球形成,并促进分化,为开发 HDACi 作为治疗 GBM 的潜在治疗方法提供了进一步的证据。